EQT Life Sciences — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Atalanta is a mathematical AI company that provides software verification and formal methods capabilities to ensure provably correct decision-making in complex systems for high-stakes missions in energy, space, and defense sectors.
AI & Machine LearningDeep TechDefense Tech
Jonathan Ring(Founder)in
Co-investorsFelicis Venturesabrdn plcF-Prime Capital
Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.
BiotechHealthtech
Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture PartnersSanofi Venturesabrdn plc
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)
BoardJoyce Erony(Director)inWilliam Harrington(Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTForbion+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.